← All diseases Infectious diseases

Chronic hepatitis B

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (82)Meta-analysis (26)Treatment guideline (6)Randomized trial (32)Systematic review (10)Phase 3 study (8)Clinical trial (630)Review article (169)Early study (phase 1 or 2) (25)Case reports (96)Laboratory or animal research (16)Commentary or Editorial (50)Retracted publication (2) Studies currently recruiting participants only (31)

Filter

Publications and studies (2004)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B (2025-01-09) ♡
• Identification of RAD51AP1 as a key gene in hepatitis B virus-associated hepatocellular carcinoma. (2024/12/31) ♡
• Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection. (2024/12/31) ♡
• Diversity and inclusion in chronic hepatitis B randomised controlled trials: A systematic meta-epidemiological review. (2024/12/31) ♡
• Potential role of liver-resident CD3(+) macrophages in HBV clearance in a mouse hepatitis B model. (2024/12/31) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study. (2024/12/30) ♡
• PR/SET domain 1 targeting glutathione peroxidase 4 regulates chronic hepatitis B liver fibrosis through ferroptosis. (2024/12/30) ♡
• [Long-term therapeutic outcomes of antiviral treatment in patients with chronic hepatitis B infection with normal alanine aminotransferase, mild liver inflammation, and fibrosis]. (2024/12/30) ♡
• [Study on the efficacy and safety profile of tenofovir alafenamide fumarate in the treatment of patients with decompensated hepatitis B cirrhosis]. (2024/12/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A case of chronic hepatitis B patient with sequential treatment of tenofovir and pegylated interferon alpha]. (2024/12/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A case of chronic hepatitis B who achieved clinical cure with pegylated interferon alfa intermittent and combination therapy]. (2024/12/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A clinically cured case of chronic hepatitis B]. (2024/12/30) ♡
• [Immune status of inactive HBsAg antigen carriers with chronic HBV infection]. (2024/12/30) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Urinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study. (2024/12/27) ♡
• Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection. (2024/12/27) ♡
• Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus. (2024/12/27) ♡
• Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances. (2024/12/27) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Revolutionizing the understanding of liver disease: Metabolism, function and future. (2024/12/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention. (2024/12/27) ♡
• Inhibition of hepatitis B virus through PPAR-JAK/STAT pathway modulation by electroacupuncture and tenofovir disoproxil fumarate combination therapy. (2024/12/25) ♡
• Exploration of the Role of Cyclophilins in Established Hepatitis B and C Infections. (2024/12/25) ♡
• Probability analysis of hepatocellular carcinoma in hepatitis patients in the gray zone. (2024/12/24) ♡
• Correlation Between Clinical Indicators and Liver Pathology in Children with Chronic Hepatitis B. (2024/12/20) ♡
• Plasma Interleukin-35 Levels Predict the Prognosis in Patients with HBV-Related Acute-on-Chronic Liver Failure. (2024/12/20) ♡
• [Comparison of the effects of tenofovir amibufenamide and tenofovir alafenamide on lipid metabolism in the body]. (2024/12/20) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Association of Chronic Hepatitis B With Colorectal Cancer and Its Dual Impact on Colorectal Liver Metastasis: A Narrative Review. (2024/12/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Severe liver injury induced by minocycline in hepatitis B patient: a Case Report. (2024/12/19) ♡
• Characterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA. (2024/12/19) ♡
• Cohort Profile: The Chronic Hepatitis B Infection and Liver Disease (HEPCARE) study in Jiangsu, China. (2024/12/16) ♡
• Clinical effectiveness of entecavir versus tenofovir disoproxil fumarate tablets in chronic hepatitis B treatment. (2024/12/15) ♡
• Transcriptomic and metabolomic analyses reveal the spatial role of carnitine metabolism in the progression of hepatitis B virus cirrhosis to hepatocellular carcinoma. (2024/12/13) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B. (2024/12/13) ♡
• Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand. (2024/12/11) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA. (2024/12/07) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. (2024/12/05) ♡
• Data characterizing a panel of biodegradable cross-linked polyester implants for sustained delivery of an anti-viral drug. (2024/12/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B. (2024/12/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Association of vitamin D with functional cure in chronic hepatitis B: Insights from a retrospective cohort study and an intervention study. (2024/12/01) ♡
• Exploring the Role of Long Non-Coding RNAs in Predicting Outcomes for Hepatitis B Patients. (2024/12/01) ♡
• The salivary microbiome and oral health status in HBeAg-negative chronic hepatitis B. (2024/12/01) ♡
• Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B. (2024/12/01) ♡
• Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease. (2024/12/01) ♡
• [Let's start from practical for returning academics to the clinic]. (2024/11/30) ♡
• [Clinical efficacy of switching to tenofovir amibufenamide tablets with poor response to entecavir in patients with chronic hepatitis B]. (2024/11/30) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. [Observation on the efficacy of Zhenqi Fuzheng capsule combined with tenofovir amibufenamide in the treatment of chronic hepatitis B]. (2024/11/30) ♡
• [Switching to TMF rescue therapy in patients developing low-level viremia with ETV or TAF treatment]. (2024/11/30) ♡
• [Evaluation of the efficacy and safety profile of tenofovir amibufenamide at 48 weeks during the treatment of hepatitis B virus-related cirrhosis]. (2024/11/30) ♡
• [Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis]. (2024/11/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [A case of tenofovir amibufenamide rescue treatment in entecavir-resistance combined with renal insufficiency]. (2024/11/30) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Tenofovir amibufenamide combined with pegylated interferon α-2b in treatment of chronic hepatitis B patients with low-level viremia: a case report]. (2024/11/30) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.